医药前沿
醫藥前沿
의약전연
YIAYAO QIANYAN
2015年
16期
55-56,57
,共3页
重组人白介素-11%鼻咽癌%口腔粘膜炎%放射性治疗
重組人白介素-11%鼻嚥癌%口腔粘膜炎%放射性治療
중조인백개소-11%비인암%구강점막염%방사성치료
Recombinant human interleukin-11%Nasopharyngeal carcinoma%Oral mucositis%Radiotherapy
目的：观察重组人白介素-11( IL-11)在防治鼻咽癌放射治疗相关性口腔粘膜炎的疗效。方法选取2013年3月～2014年12月在我院肿瘤科就诊的鼻咽癌患者58例，随机分为重组人白介素-11组（n=30）及生理盐水组(n=28)，从放疗第一天开始至放疗，当两组患者出现II级及以上口腔粘膜炎时予常规对症处理。观察两组黏膜炎发生率，发生时间，反应程度及不了反应等。结果1.重组人白介素-11组和对照组I级与III级粘膜炎发生率分别为46.7%和3.60%，16.7%和42.8%(P<0.05)；2.在照射剂量达20Gy及30Gy时，白介素-11组口腔粘膜炎发生率分别为33.3%和63.4%，而对照组分别为78.5%和21.5%(P<0.05)；3.白介素-11组出现粘膜炎的时间是中位18天，对照组是中位11天( P<0.05)；4.重组人白介素-11和对照组I I I级粘膜炎平均持续时间分别为8.2天和11.4天(P<0.05)。结论重组人白介素-11含漱对防治鼻咽癌放射性口腔粘膜炎有较好的效果，明显推迟口腔粘膜反应出现时间，缩短粘膜修复时间，粘膜反应程度多为Ⅰ级，值得临床推广。
目的：觀察重組人白介素-11( IL-11)在防治鼻嚥癌放射治療相關性口腔粘膜炎的療效。方法選取2013年3月～2014年12月在我院腫瘤科就診的鼻嚥癌患者58例，隨機分為重組人白介素-11組（n=30）及生理鹽水組(n=28)，從放療第一天開始至放療，噹兩組患者齣現II級及以上口腔粘膜炎時予常規對癥處理。觀察兩組黏膜炎髮生率，髮生時間，反應程度及不瞭反應等。結果1.重組人白介素-11組和對照組I級與III級粘膜炎髮生率分彆為46.7%和3.60%，16.7%和42.8%(P<0.05)；2.在照射劑量達20Gy及30Gy時，白介素-11組口腔粘膜炎髮生率分彆為33.3%和63.4%，而對照組分彆為78.5%和21.5%(P<0.05)；3.白介素-11組齣現粘膜炎的時間是中位18天，對照組是中位11天( P<0.05)；4.重組人白介素-11和對照組I I I級粘膜炎平均持續時間分彆為8.2天和11.4天(P<0.05)。結論重組人白介素-11含漱對防治鼻嚥癌放射性口腔粘膜炎有較好的效果，明顯推遲口腔粘膜反應齣現時間，縮短粘膜脩複時間，粘膜反應程度多為Ⅰ級，值得臨床推廣。
목적：관찰중조인백개소-11( IL-11)재방치비인암방사치료상관성구강점막염적료효。방법선취2013년3월～2014년12월재아원종류과취진적비인암환자58례，수궤분위중조인백개소-11조（n=30）급생리염수조(n=28)，종방료제일천개시지방료，당량조환자출현II급급이상구강점막염시여상규대증처리。관찰량조점막염발생솔，발생시간，반응정도급불료반응등。결과1.중조인백개소-11조화대조조I급여III급점막염발생솔분별위46.7%화3.60%，16.7%화42.8%(P<0.05)；2.재조사제량체20Gy급30Gy시，백개소-11조구강점막염발생솔분별위33.3%화63.4%，이대조조분별위78.5%화21.5%(P<0.05)；3.백개소-11조출현점막염적시간시중위18천，대조조시중위11천( P<0.05)；4.중조인백개소-11화대조조I I I급점막염평균지속시간분별위8.2천화11.4천(P<0.05)。결론중조인백개소-11함수대방치비인암방사성구강점막염유교호적효과，명현추지구강점막반응출현시간，축단점막수복시간，점막반응정도다위Ⅰ급，치득림상추엄。
Objective To observe the efficacy of recombinant human interleukin-11 ( IL-11) in treatment of oral mucositis related with nasopharyngeal carcinoma(NPC) radiotherapy.Methods 58 cases (from Mar 2013 to Dec 2014) with NPC were randomly divided into the observation group (recombinant human interleukin -11 group n = 30) and the control group (nomal saline group n = 28) . The patients were given conventional treatment if oral mucositis grade were II –IV.Results 1.The incidences of grade I were 46.7% , 3.60% and the incidences of grade III were 16.7%, 42.8% in the observation group and control group respectively(P < 0. 05) .2. in the observation group, the rate of radioactive mucositis at 20Gy and 30Gy was 33.3% and 63.4% respectively, which in the control group was 78.5% and 21.5% respectively(P < 0. 05). 3. The median time of occurrence on radiation mucositis in the observation group and in the control group was 18 and 11days respectively (P < 0. 05). 4. The mean time for radioactive oral mucositis of grade III lasting in the observation group and in the control group was 8.2 and 11.4 days respectively(P < 0. 05).Conclusions Compound recombinant human interleukin-11 solution is effective to prevent and treat the radiotherapy - induced oral mucositis reaction. It has no side effects. So it is valuable for clinical application.
